Strontium (Sr) ranelate is a new anti‐osteoporosis drug, which has the potential to reduce the vertebral and non‐vertebral fracture risks in postmenopausal women.1-3 In clinical trials, Sr ranelate (SrR) has been demonstrated to significantly increase bone formation markers and decrease bone resorption markers.1 Histomorphometric analysis of bone biopsies from osteoporosis patients suggested that SrR increases osteoblast surface and mineral apposition rate, accompanied with a decrease of osteoclast surface.4 In addition, micro‐computer tomography (µCT) analysis of bone biopsies suggested SrR increased trabecular number while it decreased trabecular separation.4